Key result
The abstract outlines a hypothesis that perhexiline improves exercise capacity and diastolic abnormalities in HFpEF, but reports no clinical results or quantitative data.
Why the study?
Does perhexiline improve exercise capacity and diastolic abnormalities in patients with heart failure with preserved ejection fraction?
RCT
Double-blind
Randomized
Does perhexiline improve exercise capacity and diastolic abnormalities in patients with heart failure with preserved ejection fraction?
No reported results leave perhexiline's role in HFpEF unresolved; full RCT data needed to confirm or refute benefit.
Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2014) conducted an RCT in Heart Failure With Preserved Ejection Fraction (HFpEF). Perhexiline vs. Placebo was evaluated on Exercise capacity and diastolic abnormalities (hypothesized). The abstract outlines a hypothesis that perhexiline improves exercise capacity and diastolic abnormalities in HFpEF, but reports no clinical results or quantitative data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: